Replies to post #13049 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Flo,

I didn't replay but I thought that Shea said "he thought" there wouldn't be 3X damages so I interpreted that as meaning 3X was guaranteed.

He did say the decision was Sandoz's per se.

[t57]

they could "launch" at risk by introducing their price, penetrating the various layers of insurance gatekeepers and not necessarily book a lot of business but regardless the mere approval validates their science.

[indigokid]

Listened to webcast and Shea said in his opinion there wouldn't be 3x damages which I infer is because he thinks the patent will be overturned at the CAFC when the case eventually gets resolved. That is still likely 12-18 months away.

It appears their optimism on copaxone approval was a result of no further questions from the FDA around R&D day in Oct. Which now appears to be frustration since 4 months later still no final CP answer and that there is no reason review should take more than 7 years.

Obviously FDA approval regardless of at risk launch would be significant validation for MNTA.